NASDAQ:AVEO

AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News

$7.69

-0.05 (-0.65%)

(As of 08/18/2022 12:00 AM ET)

Add

Compare

Today's Range: $7.12
▼
$7.78
50-Day Range: $3.99
▼
$8.01
52-Week Range: $3.06
▼
$8.25

Volume: 253,815 shs
Average Volume: 285,617 shs
Market Capitalization: $266.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

AVEO Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 133.8% Upside
$18.00 Price Target
Short Interest: Healthy
3.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.11
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.94) to $0.41 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

426th out of 1,119 stocks

Pharmaceutical Preparations Industry

209th out of 549 stocks

3.5

Analyst's Opinion

Consensus Rating
AVEO Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, AVEO Pharmaceuticals has a forecasted upside of 133.8% from its current price of $7.70.
Amount of Analyst Coverage
AVEO Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.59% of the float of AVEO Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
AVEO Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in AVEO Pharmaceuticals has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AVEO Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AVEO Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVEO.

4.0

News and Social Media Coverage

News Sentiment
AVEO Pharmaceuticals has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for AVEO Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
12 people have searched for AVEO on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
7 people have added AVEO Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVEO Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of AVEO Pharmaceuticals is held by insiders.
Percentage Held by Institutions
52.61% of the stock of AVEO Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AVEO Pharmaceuticals are expected to grow in the coming year, from ($0.94) to $0.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVEO Pharmaceuticals is -7.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVEO Pharmaceuticals is -7.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVEO Pharmaceuticals has a P/B Ratio of 8.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AVEO Pharmaceuticals (NASDAQ:AVEO) Stock

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. SVB Leerink reaffirmed an "outperform" rating on shares of AVEO Pharmaceuticals in a research note on Wednesday, July 27th. StockNews.com raised shares of AVEO Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Monday.

AVEO Pharmaceuticals Price Performance

AVEO traded down $0.04 on Thursday, hitting $7.70. The company had a trading volume of 3,355 shares, compared to its average volume of 233,081. The company has a quick ratio of 3.06, a current ratio of 3.10 and a debt-to-equity ratio of 1.09. AVEO Pharmaceuticals has a 1 year low of $3.06 and a 1 year high of $8.25. The company's fifty day moving average price is $6.56 and its 200 day moving average price is $5.21.

AVEO Pharmaceuticals (NASDAQ:AVEO - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. AVEO Pharmaceuticals had a negative return on equity of 87.81% and a negative net margin of 45.72%. During the same quarter in the prior year, the business posted ($0.48) earnings per share. As a group, equities analysts expect that AVEO Pharmaceuticals will post -0.94 earnings per share for the current fiscal year.

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Stock News Headlines

August 17, 2022 | americanbankingnews.com

AVEO Pharmaceuticals (NASDAQ:AVEO) Raised to Buy at StockNews.com

August 15, 2022 | seekingalpha.com

A Current Assessment On AVEO Pharmaceuticals

August 10, 2022 | finance.yahoo.com

Wall Street Analysts Believe AVEO (AVEO) Could Rally 113%: Here's is How to Trade

August 9, 2022 | finance.yahoo.com

Recent Price Trend in AVEO (AVEO) is Your Friend, Here's Why

August 6, 2022 | seekingalpha.com

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2022 Results - Earnings Call Transcript

August 6, 2022 | americanbankingnews.com

AVEO Pharmaceuticals (NASDAQ:AVEO) Stock Crosses Above 200 Day Moving Average of $4.97

August 5, 2022 | uk.finance.yahoo.com

AVEO Pharmaceuticals, Inc. (AVEO)

August 3, 2022 | msn.com

AVEO Pharmaceuticals Earnings Preview

July 31, 2022 | americanbankingnews.com

AVEO Pharmaceuticals (NASDAQ:AVEO) Rating Reiterated by SVB Leerink

July 28, 2022 | finance.yahoo.com

AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022

July 14, 2022 | msn.com

Why You Should Avoid The 2011 Chevrolet Aveo

June 22, 2022 | finance.yahoo.com

Strong week for AVEO Pharmaceuticals (NASDAQ:AVEO) shareholders doesn't alleviate pain of five-year loss

June 22, 2022 | finance.yahoo.com

AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC

June 21, 2022 | finance.yahoo.com

AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients

June 10, 2022 | marketwatch.com

Nasopharyngeal Cancer Drug Market Size Competitive Landscape, Key players, New Developments, Consumer Insights, and Strategies

June 6, 2022 | finance.yahoo.com

AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting

May 26, 2022 | msn.com

Looking Into AVEO Pharmaceuticals's Return On Capital Employed

May 26, 2022 | apnews.com

Worldwide Cancer Cachexia Industry to 2027 - Featuring Aphios, Artelo Biosciences and AVEO Pharmaceuticals Among Others - ResearchAndMarkets.com

May 24, 2022 | seekingalpha.com

AVEO Pharmaceuticals Is Primed For A Breakout

May 18, 2022 | finance.yahoo.com

AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference

May 8, 2022 | finance.yahoo.com

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 6, 2022 | finance.yahoo.com

Is AVEO Pharmaceuticals (NASDAQ:AVEO) A Risky Investment?

May 5, 2022 | seekingalpha.com

AVEO Pharmaceuticals' (AVEO) CEO Michael Bailey on Q1 2022 Results - Earnings Call Transcript

May 5, 2022 | finance.yahoo.com

AVEO Oncology Reports First Quarter 2022 Financial Results

May 4, 2022 | seekingalpha.com

AVEO Pharmaceuticals Q1 2022 Earnings Preview

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Company Calendar

Last Earnings: 8/04/2022
Today: 8/18/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:AVEO
CUSIP: 05358810
CIK: 1325879
Web: www.aveooncology.com
Phone: (617) 400-0101
Fax: 617-995-4995
Employees: 114
Year Founded: 2001

Price Target and Rating

Average Stock Price Forecast: $18.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +134.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,340,000.00
Net Margins: -45.72%
Pretax Margin: -45.72%
Return on Equity: -87.81%
Return on Assets: -35.19%

Debt

Debt-to-Equity Ratio: 1.09
Current Ratio: 3.10
Quick Ratio: 3.06

Sales & Book Value

Annual Sales: $42.29 million
Price / Sales: 6.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.88 per share
Price / Book: 8.74

Miscellaneous

Outstanding Shares: 34,614,000
Free Float: 33,576,000
Market Cap: $266.18 million
Optionable: Optionable
Beta: 0.79

Social Links

Key Executives

Mr. Michael P. Bailey (Age 57)
CEO, Pres & Director
Comp: $967.12k

Mr. Erick J. Lucera CFA (Age 54)
CPA, Chief Financial Officer
Comp: $524.21k

Mr. Michael Ferraresso (Age 48)
Chief Commercial Officer
Comp: $531.55k

Mr. Jeb Ledell
Chief Operating Officer

Dr. Emile Farhan
Sr. VP of Technical Operations & Quality Assurance

Ms. Danielle Holland
VP of Legal & Corp. Sec.

Mr. Kevin Peacock
Sr. VP of Marketing

Mr. David Crist
VP of Sales

Ms. Catherine DeRose
VP of HR

Ms. Anisha Wharton
Head of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVEO Stock - Frequently Asked Questions

Should I buy or sell AVEO Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVEO shares.
View AVEO analyst ratings or view top-rated stocks.
What is AVEO Pharmaceuticals' stock price forecast for 2022?: 2 Wall Street analysts have issued twelve-month target prices for AVEO Pharmaceuticals' stock. Their AVEO share price forecasts range from $18.00 to $18.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 134.1% from the stock's current price.
View analysts price targets for AVEO or view top-rated stocks among Wall Street analysts.
How have AVEO shares performed in 2022?: AVEO Pharmaceuticals' stock was trading at $4.69 at the beginning of 2022. Since then, AVEO stock has increased by 64.0% and is now trading at $7.69.
View the best growth stocks for 2022 here.
When is AVEO Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVEO earnings forecast.
How were AVEO Pharmaceuticals' earnings last quarter?: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. AVEO Pharmaceuticals had a negative net margin of 45.72% and a negative trailing twelve-month return on equity of 87.81%. During the same period in the prior year, the company posted ($0.48) EPS.
When did AVEO Pharmaceuticals' stock split?: Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?: 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

What other stocks do shareholders of AVEO Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).
What is AVEO Pharmaceuticals' stock symbol?: AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
Who are AVEO Pharmaceuticals' major shareholders?: AVEO Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.86%), Renaissance Technologies LLC (0.36%), Brandywine Global Investment Management LLC (0.32%), Northern Trust Corp (0.15%), Goldman Sachs Group Inc. (0.06%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends.
How do I buy shares of AVEO Pharmaceuticals?: Shares of AVEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AVEO Pharmaceuticals' stock price today?: One share of AVEO stock can currently be purchased for approximately $7.69.
How much money does AVEO Pharmaceuticals make?: AVEO Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $266.18 million and generates $42.29 million in revenue each year. The biopharmaceutical company earns $-53,340,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.
How many employees does AVEO Pharmaceuticals have?: The company employs 114 workers across the globe.
When was AVEO Pharmaceuticals founded?: AVEO Pharmaceuticals was founded in 2001.
How can I contact AVEO Pharmaceuticals?: AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The official website for the company is www.aveooncology.com. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at ir@aveooncology.com, or via fax at 617-995-4995.

This page (NASDAQ:AVEO) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News

AVEO Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month